CA2756887C - Indole derivatives - Google Patents
Indole derivatives Download PDFInfo
- Publication number
- CA2756887C CA2756887C CA2756887A CA2756887A CA2756887C CA 2756887 C CA2756887 C CA 2756887C CA 2756887 A CA2756887 A CA 2756887A CA 2756887 A CA2756887 A CA 2756887A CA 2756887 C CA2756887 C CA 2756887C
- Authority
- CA
- Canada
- Prior art keywords
- imaging agent
- vivo imaging
- ethyl
- precursor compound
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16413109P | 2009-03-27 | 2009-03-27 | |
| GBGB0905328.1A GB0905328D0 (en) | 2009-03-27 | 2009-03-27 | Indole derivatives |
| GB0905328.1 | 2009-03-27 | ||
| US61/164,131 | 2009-03-27 | ||
| PCT/EP2010/053998 WO2010109007A2 (en) | 2009-03-27 | 2010-03-26 | Indole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2756887A1 CA2756887A1 (en) | 2010-09-30 |
| CA2756887C true CA2756887C (en) | 2018-06-19 |
Family
ID=40671850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2756887A Active CA2756887C (en) | 2009-03-27 | 2010-03-26 | Indole derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8790619B2 (enExample) |
| EP (1) | EP2411362B1 (enExample) |
| JP (1) | JP5651163B2 (enExample) |
| KR (1) | KR101692090B1 (enExample) |
| CN (1) | CN102448933B (enExample) |
| AU (1) | AU2010227527B2 (enExample) |
| BR (1) | BRPI1010261A2 (enExample) |
| CA (1) | CA2756887C (enExample) |
| ES (1) | ES2635310T3 (enExample) |
| GB (1) | GB0905328D0 (enExample) |
| IL (1) | IL215019A0 (enExample) |
| MX (1) | MX2011010154A (enExample) |
| NZ (1) | NZ595227A (enExample) |
| RU (1) | RU2525196C2 (enExample) |
| SG (1) | SG174589A1 (enExample) |
| WO (1) | WO2010109007A2 (enExample) |
| ZA (1) | ZA201106708B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905328D0 (en) | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| SG183837A1 (en) * | 2010-03-26 | 2012-10-30 | Ge Healthcare Ltd | Tricyclic indole derivatives as pbr ligands |
| GB201016038D0 (en) | 2010-09-24 | 2010-11-10 | Ge Healthcare Ltd | In vivo imaging method |
| GB201016411D0 (en) * | 2010-09-30 | 2010-11-10 | Ge Healthcare Ltd | In vivo imaging method for cancer |
| GB201021263D0 (en) * | 2010-12-15 | 2011-01-26 | Ge Healthcare Ltd | Solid phase extraction method |
| EP2694505B1 (en) * | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| US20140301947A1 (en) | 2011-06-06 | 2014-10-09 | Imperial Innovations Limited | Methods to predict binding affinity of tspo imaging agents to tspo |
| AU2012315757B9 (en) * | 2011-09-30 | 2018-01-25 | Ge Healthcare Limited | Calibration and normalization systems and methods for radiopharmaceutical synthesizers |
| US10709798B2 (en) | 2012-11-30 | 2020-07-14 | Ge Healthcare Limited | Crystallization process of tricyclic indole derivatives |
| CN104797559A (zh) * | 2012-11-30 | 2015-07-22 | 通用电气健康护理有限公司 | 卤化锌介导的环化过程得到三环吲哚 |
| GB201312768D0 (en) | 2013-07-17 | 2013-08-28 | Ge Healthcare Ltd | Work-up procedure |
| GB201316762D0 (en) * | 2013-09-20 | 2013-11-06 | Ge Healthcare Ltd | Novel compounds |
| GB201316766D0 (en) * | 2013-09-20 | 2013-11-06 | Ge Healthcare Uk Ltd | Macrophage Imaging |
| GB201316764D0 (en) * | 2013-09-20 | 2013-11-06 | Ge Healthcare Ltd | Novel compounds |
| KR102668112B1 (ko) | 2014-12-04 | 2024-05-23 | 지이 헬쓰케어 리미티드 | 방사성 약제로부터의 아세트알데히드의 제거 방법 |
| CN106748802B (zh) * | 2016-12-26 | 2018-11-13 | 南京理工大学 | 一种制备含氟仲胺的方法 |
| WO2018218025A1 (en) * | 2017-05-24 | 2018-11-29 | The Trustees Of The University Of Pennsylvania | Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy |
| US11200669B2 (en) * | 2019-11-19 | 2021-12-14 | Uih America, Inc. | Systems and methods for determining plasma input function used in positron emission tomography imaging |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| FR2599740B1 (fr) * | 1986-06-05 | 1988-08-12 | Rhone Poulenc Sante | Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant |
| US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| WO1999025340A1 (en) | 1997-11-14 | 1999-05-27 | Eli Lilly And Company | Treatment for alzheimer's disease |
| JPH11228539A (ja) * | 1997-12-03 | 1999-08-24 | Taisho Pharmaceut Co Ltd | 含窒素四環性化合物 |
| US6281355B1 (en) * | 1997-12-03 | 2001-08-28 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing tetracyclic compounds |
| DE69930308T2 (de) * | 1998-12-11 | 2006-11-30 | Virginia Commonwealth University | Selektive 5-ht 6-rezeptor-liganden |
| FR2788776B1 (fr) | 1999-01-26 | 2001-02-23 | Synthelabo | Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique |
| GB0115929D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase electrophilic fluorination |
| GB0115927D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
| JP2005527464A (ja) | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体 |
| JP2005527466A (ja) | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体 |
| GB0523506D0 (en) | 2005-11-18 | 2005-12-28 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
| GB0905328D0 (en) | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
-
2009
- 2009-03-27 GB GBGB0905328.1A patent/GB0905328D0/en not_active Ceased
-
2010
- 2010-03-26 RU RU2011138850/04A patent/RU2525196C2/ru active
- 2010-03-26 JP JP2012501315A patent/JP5651163B2/ja active Active
- 2010-03-26 ES ES10710356.6T patent/ES2635310T3/es active Active
- 2010-03-26 AU AU2010227527A patent/AU2010227527B2/en active Active
- 2010-03-26 SG SG2011070018A patent/SG174589A1/en unknown
- 2010-03-26 BR BRPI1010261A patent/BRPI1010261A2/pt not_active Application Discontinuation
- 2010-03-26 US US13/258,465 patent/US8790619B2/en active Active
- 2010-03-26 CN CN201080023868.3A patent/CN102448933B/zh active Active
- 2010-03-26 MX MX2011010154A patent/MX2011010154A/es active IP Right Grant
- 2010-03-26 KR KR1020117025305A patent/KR101692090B1/ko active Active
- 2010-03-26 WO PCT/EP2010/053998 patent/WO2010109007A2/en not_active Ceased
- 2010-03-26 CA CA2756887A patent/CA2756887C/en active Active
- 2010-03-26 NZ NZ595227A patent/NZ595227A/xx unknown
- 2010-03-26 EP EP10710356.6A patent/EP2411362B1/en active Active
- 2010-09-13 US US12/880,218 patent/US8501153B2/en active Active
-
2011
- 2011-09-07 IL IL215019A patent/IL215019A0/en not_active IP Right Cessation
- 2011-09-13 ZA ZA2011/06708A patent/ZA201106708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102448933A (zh) | 2012-05-09 |
| CA2756887A1 (en) | 2010-09-30 |
| JP5651163B2 (ja) | 2015-01-07 |
| US20110070161A1 (en) | 2011-03-24 |
| ES2635310T3 (es) | 2017-10-03 |
| US8790619B2 (en) | 2014-07-29 |
| US20120020884A1 (en) | 2012-01-26 |
| KR20110133492A (ko) | 2011-12-12 |
| WO2010109007A2 (en) | 2010-09-30 |
| EP2411362B1 (en) | 2017-05-31 |
| IL215019A0 (en) | 2011-11-30 |
| HK1167393A1 (en) | 2012-11-30 |
| BRPI1010261A2 (pt) | 2016-03-22 |
| JP2012521973A (ja) | 2012-09-20 |
| AU2010227527B2 (en) | 2015-03-12 |
| CN102448933B (zh) | 2014-07-02 |
| AU2010227527A1 (en) | 2011-10-13 |
| WO2010109007A3 (en) | 2010-11-25 |
| MX2011010154A (es) | 2011-10-21 |
| GB0905328D0 (en) | 2009-05-13 |
| RU2011138850A (ru) | 2013-05-10 |
| KR101692090B1 (ko) | 2017-01-02 |
| NZ595227A (en) | 2013-11-29 |
| ZA201106708B (en) | 2013-02-27 |
| SG174589A1 (en) | 2011-10-28 |
| EP2411362A2 (en) | 2012-02-01 |
| RU2525196C2 (ru) | 2014-08-10 |
| US8501153B2 (en) | 2013-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2756887C (en) | Indole derivatives | |
| US9314541B2 (en) | In vivo imaging method for cancer | |
| US9168317B2 (en) | In vivo imaging method of mood disorders | |
| JP5730206B2 (ja) | 神経炎症のイメージング | |
| US20120003154A1 (en) | Aryloxyanilide derivatives | |
| US9220795B2 (en) | Indole derivatives | |
| HK1167393B (en) | Tricyclic indole derivates as pbr ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150313 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250227 |